-+ 0.00%
-+ 0.00%
-+ 0.00%

Opus Genetics to report Phase 1/2 Cohort 1 topline data for OPGx-BEST1 gene therapy Sept. 9 webcast

PUBT·09/02/2026 11:01:16
Listen to the news
Opus Genetics to report Phase 1/2 Cohort 1 topline data for OPGx-BEST1 gene therapy Sept. 9 webcast
  • Opus Genetics set a Sept. 9, 2026 investor webcast to present topline Phase 1/2 Cohort 1 data for OPGx-BEST1.
  • Results have not been presented yet; broader analyses are scheduled for release at ophthalmology conferences later in September and October 2026.
  • The readout will cover early clinical performance of a gene therapy aimed at improving vision outcomes in inherited retinal disease tied to BEST1 mutations.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609020700PRIMZONEFULLFEED9819950) on September 02, 2026, and is solely responsible for the information contained therein.